Prognostic implications of receptor discordance between primary and recurrent breast cancer
Authors:
- 29 October 2014
- journal article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 20 (4) , 701-708
Abstract
Discordance rates of hormone receptor (HR) and human epidermal growth factor-2 (HER2) status between primary and recurrent breast cancer were reported to be in the wide range of 10–40 %, although its prognostic relevance remains to be elucidated. Fifty-five breast cancer patients had biopsies or resections of recurrent lesions. Pathological assessments of the HR and HER2 status of primary and recurrent lesions were performed in a single laboratory at Keio University Hospital. Tumors were classified as luminal (HR+ and HER2−), luminal/HER2 (HR+ and HER2+), HER2 (HR− and HER2+), or triple negative (HR− and HER2−). Discordance rates in estrogen receptor (ER), progesterone receptor (PgR) and HER2 status between primary tumors and recurrent lesions were 16.4, 30.9 and 10.2 %, respectively. Overall, 14 patients (25.5 %) changed subtypes at recurrent lesions. Patients with a gain in ER and PgR status had a significantly longer disease-free interval compared with the corresponding concordant-negative patients (ER: 99.0 vs. 18.5 months, p = 0.037, PgR: 141.0 vs. 24.4 months, p = 0.011). Patients with a loss of HER2 status experienced a trend toward shorter time to progression, compared with patients who maintained HER2 positivity (4.0 vs. 18.4 months, p = 0.051). Discordance in receptor status between primary and recurrent breast cancers were seen in 10–30 %. A gain in HR status was significantly associated with better prognosis.Keywords
This publication has 20 references indexed in Scilit:
- Biopsy of liver metastasis for women with breast cancer: Impact on survivalThe Breast, 2012
- Breast cancer — one term, many entities?Journal of Clinical Investigation, 2011
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31Journal of Clinical Oncology, 2011
- HER2 status in a population-derived breast cancer cohort: discordances during tumor progressionBreast Cancer Research and Treatment, 2010
- Does Analysis of Biomarkers in Tumor Cells in Lymph Node Metastases Give Additional Prognostic Information in Primary Breast Cancer?World Journal of Surgery, 2010
- Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival OutcomesClinical Cancer Research, 2009
- Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastasesAnnals of Oncology, 2009
- Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancerAnnals of Oncology, 2009
- Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal MetastasesClinical Cancer Research, 2008
- HER-2/neu expression in primary and metastatic breast cancerBreast Cancer Research and Treatment, 2008